Share Price and Basic Stock Data
Last Updated: December 19, 2025, 9:14 pm
| PEG Ratio | 0.19 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Natco Pharma Ltd, a prominent player in the Indian pharmaceuticals sector, has demonstrated resilience and growth in its revenue streams. For the fiscal year ending March 2025, the company reported sales of ₹4,430 Cr, a significant increase from ₹3,999 Cr in the previous year. This upward trajectory reflects not only strong demand for its products but also effective management strategies. The quarterly sales figures reveal a robust performance, peaking at ₹1,371 Cr in September 2024, which is indicative of seasonal fluctuations and market positioning. Natco’s ability to maintain a stable sales environment, even amidst industry challenges, is commendable, with a trailing twelve-month revenue of ₹4,396 Cr. This positions the company well within a competitive landscape that requires agility and innovation.
Profitability and Efficiency Metrics
Profitability metrics for Natco Pharma appear strong, with a reported net profit of ₹1,883 Cr for FY 2025, reflecting a substantial increase from ₹1,388 Cr in FY 2024. The operating profit margin (OPM) has significantly improved, standing at 50% for FY 2025, up from 44% in the previous year. Such margins are noteworthy, especially in the pharmaceutical sector, where operational efficiency is often a critical determinant of success. The return on equity (ROE) at 28% and return on capital employed (ROCE) at 33% further illustrate the company’s effective capital utilization. However, the cash conversion cycle (CCC) of 362 days may raise concerns about liquidity management, suggesting that while profitability is solid, the company needs to enhance its working capital efficiency.
Balance Sheet Strength and Financial Ratios
Natco’s balance sheet exhibits remarkable strength, characterized by low borrowings of just ₹261 Cr against reserves of ₹8,614 Cr. This translates to a debt-to-equity ratio of 0.03, indicating a conservative approach to leveraging and a strong capital structure. The interest coverage ratio of 106.72x highlights the company’s ability to easily meet its interest obligations, which is a reassuring sign for investors. Additionally, the price-to-book value ratio of 1.88x suggests that the stock is trading at a reasonable valuation relative to its net assets. However, the current ratio at 5.59 indicates an exceptionally high liquidity position, which might imply that the company is holding excess cash or liquid assets, potentially at the expense of higher returns on investments.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Natco Pharma reveals a diversified ownership structure that appears to foster confidence among investors. Promoters hold a steady 49.48% stake, reflecting their commitment to the company. Foreign institutional investors (FIIs) have increased their holdings to 14.09%, while domestic institutional investors (DIIs) account for 5.87%. Notably, public shareholding has grown to 30.56%, indicating rising interest from retail investors, which is often a positive indicator of market sentiment. The number of shareholders has also surged to 4,19,699, suggesting growing retail participation. This robust support base can provide stability to the stock price, especially during market volatility, but it also means that management must remain responsive to a broader range of stakeholder interests.
Outlook, Risks, and Final Insight
Looking ahead, Natco Pharma is well-positioned to leverage its operational strengths and market opportunities. However, it faces several risks that could impact its growth trajectory. The pharmaceutical industry is subject to stringent regulatory scrutiny, which could affect product approvals and market entry strategies. Additionally, fluctuating raw material costs and international competition could pose challenges to maintaining profit margins. While the company’s strong financial metrics indicate a solid foundation, potential investors should be cautious of these external pressures. Overall, Natco’s strong performance metrics and growing shareholder base present an attractive investment proposition, yet vigilance regarding regulatory and market dynamics will be essential for navigating the future landscape.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 151 Cr. | 120 | 235/84.3 | 33.3 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.38 Cr. | 1.77 | 4.33/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,405 Cr. | 405 | 479/192 | 91.2 | 24.3 | 0.17 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 35.7 Cr. | 48.2 | 89.8/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 48.3 Cr. | 33.0 | 33.0/17.0 | 115 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,165.63 Cr | 1,151.80 | 52.58 | 202.18 | 0.35% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 885 | 432 | 492 | 898 | 1,140 | 1,031 | 759 | 1,068 | 1,363 | 1,371 | 475 | 1,221 | 1,329 |
| Expenses | 489 | 337 | 387 | 559 | 612 | 573 | 490 | 571 | 558 | 567 | 436 | 673 | 758 |
| Operating Profit | 395 | 95 | 106 | 339 | 528 | 458 | 268 | 497 | 805 | 804 | 39 | 548 | 571 |
| OPM % | 45% | 22% | 22% | 38% | 46% | 44% | 35% | 47% | 59% | 59% | 8% | 45% | 43% |
| Other Income | 34 | 20 | 21 | 29 | 20 | 29 | 37 | 42 | 48 | 64 | 176 | 66 | 62 |
| Interest | 4 | 4 | 4 | 3 | 4 | 4 | 5 | 6 | 5 | 4 | 4 | 10 | 3 |
| Depreciation | 40 | 42 | 42 | 41 | 44 | 44 | 44 | 56 | 44 | 46 | 47 | 98 | 58 |
| Profit before tax | 386 | 70 | 81 | 324 | 500 | 440 | 256 | 478 | 804 | 818 | 164 | 506 | 572 |
| Tax % | 17% | 19% | 23% | 15% | 16% | 16% | 17% | 19% | 17% | 17% | 19% | 20% | 16% |
| Net Profit | 320 | 57 | 62 | 276 | 420 | 369 | 213 | 386 | 668 | 676 | 132 | 406 | 480 |
| EPS in Rs | 17.55 | 3.11 | 3.41 | 15.11 | 23.47 | 20.60 | 11.88 | 21.57 | 37.32 | 37.81 | 7.43 | 22.70 | 26.84 |
Last Updated: August 20, 2025, 6:25 am
Below is a detailed analysis of the quarterly data for Natco Pharma Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 1,329.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,221.00 Cr. (Mar 2025) to 1,329.00 Cr., marking an increase of 108.00 Cr..
- For Expenses, as of Jun 2025, the value is 758.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 673.00 Cr. (Mar 2025) to 758.00 Cr., marking an increase of 85.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 571.00 Cr.. The value appears strong and on an upward trend. It has increased from 548.00 Cr. (Mar 2025) to 571.00 Cr., marking an increase of 23.00 Cr..
- For OPM %, as of Jun 2025, the value is 43.00%. The value appears to be declining and may need further review. It has decreased from 45.00% (Mar 2025) to 43.00%, marking a decrease of 2.00%.
- For Other Income, as of Jun 2025, the value is 62.00 Cr.. The value appears to be declining and may need further review. It has decreased from 66.00 Cr. (Mar 2025) to 62.00 Cr., marking a decrease of 4.00 Cr..
- For Interest, as of Jun 2025, the value is 3.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 10.00 Cr. (Mar 2025) to 3.00 Cr., marking a decrease of 7.00 Cr..
- For Depreciation, as of Jun 2025, the value is 58.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 98.00 Cr. (Mar 2025) to 58.00 Cr., marking a decrease of 40.00 Cr..
- For Profit before tax, as of Jun 2025, the value is 572.00 Cr.. The value appears strong and on an upward trend. It has increased from 506.00 Cr. (Mar 2025) to 572.00 Cr., marking an increase of 66.00 Cr..
- For Tax %, as of Jun 2025, the value is 16.00%. The value appears to be improving (decreasing) as expected. It has decreased from 20.00% (Mar 2025) to 16.00%, marking a decrease of 4.00%.
- For Net Profit, as of Jun 2025, the value is 480.00 Cr.. The value appears strong and on an upward trend. It has increased from 406.00 Cr. (Mar 2025) to 480.00 Cr., marking an increase of 74.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is 26.84. The value appears strong and on an upward trend. It has increased from 22.70 (Mar 2025) to 26.84, marking an increase of 4.14.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 4:55 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 739 | 825 | 1,042 | 2,020 | 2,185 | 2,094 | 1,915 | 2,052 | 1,945 | 2,707 | 3,999 | 4,430 | 4,388 |
| Expenses | 560 | 615 | 777 | 1,337 | 1,256 | 1,300 | 1,332 | 1,446 | 1,681 | 1,772 | 2,245 | 2,234 | 2,651 |
| Operating Profit | 179 | 210 | 266 | 683 | 928 | 795 | 583 | 606 | 264 | 936 | 1,754 | 2,196 | 1,737 |
| OPM % | 24% | 25% | 25% | 34% | 42% | 38% | 30% | 30% | 14% | 35% | 44% | 50% | 40% |
| Other Income | 17 | 0 | 12 | 14 | 40 | 130 | 107 | 104 | 99 | 105 | 126 | 354 | 404 |
| Interest | 37 | 32 | 23 | 18 | 15 | 19 | 22 | 13 | 18 | 14 | 19 | 24 | 31 |
| Depreciation | 30 | 47 | 51 | 54 | 66 | 81 | 100 | 117 | 143 | 164 | 187 | 235 | 255 |
| Profit before tax | 129 | 132 | 204 | 624 | 887 | 825 | 569 | 580 | 202 | 862 | 1,674 | 2,291 | 1,855 |
| Tax % | 24% | 1% | 24% | 22% | 22% | 22% | 19% | 24% | 16% | 17% | 17% | 18% | |
| Net Profit | 98 | 130 | 156 | 485 | 695 | 642 | 458 | 442 | 170 | 715 | 1,388 | 1,883 | 1,537 |
| EPS in Rs | 6.21 | 8.10 | 9.02 | 27.88 | 37.74 | 35.24 | 25.31 | 24.18 | 9.31 | 39.18 | 77.51 | 105.26 | 85.91 |
| Dividend Payout % | 16% | 12% | 14% | 24% | 22% | 18% | 27% | 22% | 48% | 14% | 12% | 6% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 32.65% | 20.00% | 210.90% | 43.30% | -7.63% | -28.66% | -3.49% | -61.54% | 320.59% | 94.13% | 35.66% |
| Change in YoY Net Profit Growth (%) | 0.00% | -12.65% | 190.90% | -167.60% | -50.92% | -21.03% | 25.17% | -58.05% | 382.13% | -226.46% | -58.46% |
Natco Pharma Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
Last Updated: September 5, 2025, 11:35 am
Balance Sheet
Last Updated: December 4, 2025, 1:42 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 33 | 33 | 35 | 35 | 37 | 36 | 36 | 36 | 36 | 36 | 36 | 36 | 36 |
| Reserves | 693 | 813 | 1,261 | 1,614 | 3,035 | 3,452 | 3,737 | 4,085 | 4,227 | 4,837 | 5,817 | 7,571 | 8,614 |
| Borrowings | 240 | 312 | 113 | 222 | 173 | 386 | 316 | 268 | 416 | 167 | 371 | 279 | 261 |
| Other Liabilities | 229 | 226 | 413 | 446 | 470 | 428 | 498 | 403 | 430 | 617 | 682 | 744 | 1,520 |
| Total Liabilities | 1,196 | 1,384 | 1,822 | 2,318 | 3,715 | 4,303 | 4,588 | 4,792 | 5,109 | 5,657 | 6,906 | 8,631 | 10,430 |
| Fixed Assets | 645 | 710 | 710 | 833 | 1,019 | 1,227 | 1,584 | 2,023 | 2,312 | 2,427 | 2,491 | 2,698 | 2,697 |
| CWIP | 124 | 129 | 212 | 336 | 480 | 638 | 518 | 223 | 130 | 64 | 137 | 225 | 255 |
| Investments | 2 | 2 | 22 | 32 | 76 | 169 | 112 | 304 | 308 | 392 | 539 | 474 | 774 |
| Other Assets | 425 | 543 | 878 | 1,116 | 2,140 | 2,270 | 2,373 | 2,242 | 2,360 | 2,774 | 3,739 | 5,234 | 6,704 |
| Total Assets | 1,196 | 1,384 | 1,822 | 2,318 | 3,715 | 4,303 | 4,588 | 4,792 | 5,109 | 5,657 | 6,906 | 8,631 | 10,430 |
Below is a detailed analysis of the balance sheet data for Natco Pharma Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 36.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 36.00 Cr..
- For Reserves, as of Sep 2025, the value is 8,614.00 Cr.. The value appears strong and on an upward trend. It has increased from 7,571.00 Cr. (Mar 2025) to 8,614.00 Cr., marking an increase of 1,043.00 Cr..
- For Borrowings, as of Sep 2025, the value is 261.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 279.00 Cr. (Mar 2025) to 261.00 Cr., marking a decrease of 18.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 1,520.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 744.00 Cr. (Mar 2025) to 1,520.00 Cr., marking an increase of 776.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 10,430.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 8,631.00 Cr. (Mar 2025) to 10,430.00 Cr., marking an increase of 1,799.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 2,697.00 Cr.. The value appears to be declining and may need further review. It has decreased from 2,698.00 Cr. (Mar 2025) to 2,697.00 Cr., marking a decrease of 1.00 Cr..
- For CWIP, as of Sep 2025, the value is 255.00 Cr.. The value appears strong and on an upward trend. It has increased from 225.00 Cr. (Mar 2025) to 255.00 Cr., marking an increase of 30.00 Cr..
- For Investments, as of Sep 2025, the value is 774.00 Cr.. The value appears strong and on an upward trend. It has increased from 474.00 Cr. (Mar 2025) to 774.00 Cr., marking an increase of 300.00 Cr..
- For Other Assets, as of Sep 2025, the value is 6,704.00 Cr.. The value appears strong and on an upward trend. It has increased from 5,234.00 Cr. (Mar 2025) to 6,704.00 Cr., marking an increase of 1,470.00 Cr..
- For Total Assets, as of Sep 2025, the value is 10,430.00 Cr.. The value appears strong and on an upward trend. It has increased from 8,631.00 Cr. (Mar 2025) to 10,430.00 Cr., marking an increase of 1,799.00 Cr..
Notably, the Reserves (8,614.00 Cr.) exceed the Borrowings (261.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -61.00 | -102.00 | 153.00 | 461.00 | 755.00 | 409.00 | 267.00 | 338.00 | -152.00 | 769.00 | -370.00 | -277.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 59 | 85 | 92 | 86 | 106 | 88 | 105 | 73 | 116 | 115 | 109 | 103 |
| Inventory Days | 283 | 331 | 482 | 213 | 389 | 545 | 534 | 570 | 496 | 432 | 357 | 405 |
| Days Payable | 172 | 189 | 372 | 160 | 239 | 224 | 244 | 104 | 105 | 153 | 120 | 145 |
| Cash Conversion Cycle | 170 | 228 | 202 | 138 | 257 | 410 | 395 | 539 | 507 | 394 | 345 | 362 |
| Working Capital Days | 22 | 25 | 97 | 71 | 215 | 207 | 295 | 246 | 256 | 198 | 151 | 151 |
| ROCE % | 18% | 17% | 18% | 39% | 35% | 23% | 14% | 13% | 4% | 18% | 30% | 33% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Tata Value Fund | 825,000 | 0.8 | 72.37 | 1,411,475 | 2025-12-15 08:54:25 | -41.55% |
| Sundaram Small Cap Fund | 603,569 | 1.53 | 52.95 | 561,369 | 2025-12-08 07:53:01 | 7.52% |
| Tata Small Cap Fund | 549,064 | 0.42 | 48.17 | 900,000 | 2025-09-10 00:17:42 | -38.99% |
| Baroda BNP Paribas Business Cycle Fund | 72,000 | 1.07 | 6.32 | 90,000 | 2025-12-15 03:35:31 | -20% |
| Sundaram Long Term Micro Cap Tax Advantage Fund - Series III | 12,965 | 1.49 | 1.14 | N/A | N/A | N/A |
| Sundaram Long Term Micro Cap Tax Advantage Fund - Series IV | 6,109 | 1.49 | 0.54 | N/A | N/A | N/A |
| Sundaram Long Term Micro Cap Tax Advantage Fund - Series VI | 6,182 | 1.5 | 0.54 | N/A | N/A | N/A |
| Sundaram Long Term Tax Advantage Fund - Series III | 5,676 | 1.45 | 0.5 | N/A | N/A | N/A |
| Sundaram Long Term Micro Cap Tax Advantage Fund - Series V | 5,139 | 1.47 | 0.45 | N/A | N/A | N/A |
| Sundaram Long Term Tax Advantage Fund - Series IV | 3,747 | 1.46 | 0.33 | N/A | N/A | N/A |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 |
| Basic EPS (Rs.) | 105.26 | 77.34 | 39.18 | 9.32 | 24.20 |
| Diluted EPS (Rs.) | 105.26 | 77.34 | 39.18 | 9.32 | 24.16 |
| Cash EPS (Rs.) | 118.36 | 87.99 | 48.17 | 17.13 | 30.65 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 424.97 | 326.99 | 267.06 | 233.62 | 225.94 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 424.97 | 326.99 | 267.06 | 233.62 | 225.94 |
| Revenue From Operations / Share (Rs.) | 247.46 | 223.40 | 148.33 | 106.56 | 112.44 |
| PBDIT / Share (Rs.) | 142.49 | 105.00 | 57.00 | 19.86 | 38.89 |
| PBIT / Share (Rs.) | 129.35 | 94.56 | 48.02 | 12.05 | 32.49 |
| PBT / Share (Rs.) | 128.01 | 93.49 | 47.23 | 11.08 | 31.76 |
| Net Profit / Share (Rs.) | 105.22 | 77.56 | 39.19 | 9.31 | 24.24 |
| NP After MI And SOA / Share (Rs.) | 105.33 | 77.56 | 39.19 | 9.31 | 24.16 |
| PBDIT Margin (%) | 57.57 | 47.00 | 38.42 | 18.63 | 34.58 |
| PBIT Margin (%) | 52.27 | 42.33 | 32.37 | 11.30 | 28.89 |
| PBT Margin (%) | 51.73 | 41.85 | 31.83 | 10.39 | 28.24 |
| Net Profit Margin (%) | 42.51 | 34.71 | 26.42 | 8.74 | 21.55 |
| NP After MI And SOA Margin (%) | 42.56 | 34.71 | 26.42 | 8.74 | 21.48 |
| Return on Networth / Equity (%) | 24.78 | 23.71 | 14.67 | 3.98 | 10.69 |
| Return on Capital Employeed (%) | 30.11 | 28.52 | 17.61 | 4.99 | 13.89 |
| Return On Assets (%) | 21.84 | 20.10 | 12.64 | 3.32 | 9.20 |
| Total Debt / Equity (X) | 0.03 | 0.06 | 0.03 | 0.09 | 0.06 |
| Asset Turnover Ratio (%) | 0.57 | 0.63 | 0.50 | 0.36 | 0.35 |
| Current Ratio (X) | 5.59 | 4.14 | 4.39 | 3.52 | 4.45 |
| Quick Ratio (X) | 4.77 | 3.42 | 3.30 | 2.44 | 2.93 |
| Inventory Turnover Ratio (X) | 6.04 | 0.72 | 0.63 | 0.69 | 0.56 |
| Dividend Payout Ratio (NP) (%) | 5.70 | 12.25 | 14.03 | 48.29 | 25.81 |
| Dividend Payout Ratio (CP) (%) | 5.06 | 10.80 | 11.42 | 26.26 | 20.40 |
| Earning Retention Ratio (%) | 94.30 | 87.75 | 85.97 | 51.71 | 74.19 |
| Cash Earning Retention Ratio (%) | 94.94 | 89.20 | 88.58 | 73.74 | 79.60 |
| Interest Coverage Ratio (X) | 106.72 | 97.89 | 71.74 | 20.48 | 53.37 |
| Interest Coverage Ratio (Post Tax) (X) | 79.80 | 73.31 | 50.33 | 10.60 | 34.26 |
| Enterprise Value (Cr.) | 12381.23 | 16442.15 | 9905.31 | 14018.63 | 15043.09 |
| EV / Net Operating Revenue (X) | 2.80 | 4.11 | 3.66 | 7.21 | 7.33 |
| EV / EBITDA (X) | 4.85 | 8.75 | 9.52 | 38.67 | 21.19 |
| MarketCap / Net Operating Revenue (X) | 3.22 | 4.26 | 3.80 | 7.11 | 7.34 |
| Retention Ratios (%) | 94.29 | 87.74 | 85.96 | 51.70 | 74.18 |
| Price / BV (X) | 1.88 | 2.91 | 2.11 | 3.24 | 3.65 |
| Price / Net Operating Revenue (X) | 3.22 | 4.26 | 3.80 | 7.11 | 7.34 |
| EarningsYield | 0.13 | 0.08 | 0.06 | 0.01 | 0.02 |
After reviewing the key financial ratios for Natco Pharma Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 2.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 2.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 105.26. This value is within the healthy range. It has increased from 77.34 (Mar 24) to 105.26, marking an increase of 27.92.
- For Diluted EPS (Rs.), as of Mar 25, the value is 105.26. This value is within the healthy range. It has increased from 77.34 (Mar 24) to 105.26, marking an increase of 27.92.
- For Cash EPS (Rs.), as of Mar 25, the value is 118.36. This value is within the healthy range. It has increased from 87.99 (Mar 24) to 118.36, marking an increase of 30.37.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 424.97. It has increased from 326.99 (Mar 24) to 424.97, marking an increase of 97.98.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 424.97. It has increased from 326.99 (Mar 24) to 424.97, marking an increase of 97.98.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 247.46. It has increased from 223.40 (Mar 24) to 247.46, marking an increase of 24.06.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 142.49. This value is within the healthy range. It has increased from 105.00 (Mar 24) to 142.49, marking an increase of 37.49.
- For PBIT / Share (Rs.), as of Mar 25, the value is 129.35. This value is within the healthy range. It has increased from 94.56 (Mar 24) to 129.35, marking an increase of 34.79.
- For PBT / Share (Rs.), as of Mar 25, the value is 128.01. This value is within the healthy range. It has increased from 93.49 (Mar 24) to 128.01, marking an increase of 34.52.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 105.22. This value is within the healthy range. It has increased from 77.56 (Mar 24) to 105.22, marking an increase of 27.66.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 105.33. This value is within the healthy range. It has increased from 77.56 (Mar 24) to 105.33, marking an increase of 27.77.
- For PBDIT Margin (%), as of Mar 25, the value is 57.57. This value is within the healthy range. It has increased from 47.00 (Mar 24) to 57.57, marking an increase of 10.57.
- For PBIT Margin (%), as of Mar 25, the value is 52.27. This value exceeds the healthy maximum of 20. It has increased from 42.33 (Mar 24) to 52.27, marking an increase of 9.94.
- For PBT Margin (%), as of Mar 25, the value is 51.73. This value is within the healthy range. It has increased from 41.85 (Mar 24) to 51.73, marking an increase of 9.88.
- For Net Profit Margin (%), as of Mar 25, the value is 42.51. This value exceeds the healthy maximum of 10. It has increased from 34.71 (Mar 24) to 42.51, marking an increase of 7.80.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 42.56. This value exceeds the healthy maximum of 20. It has increased from 34.71 (Mar 24) to 42.56, marking an increase of 7.85.
- For Return on Networth / Equity (%), as of Mar 25, the value is 24.78. This value is within the healthy range. It has increased from 23.71 (Mar 24) to 24.78, marking an increase of 1.07.
- For Return on Capital Employeed (%), as of Mar 25, the value is 30.11. This value is within the healthy range. It has increased from 28.52 (Mar 24) to 30.11, marking an increase of 1.59.
- For Return On Assets (%), as of Mar 25, the value is 21.84. This value is within the healthy range. It has increased from 20.10 (Mar 24) to 21.84, marking an increase of 1.74.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.03. This value is within the healthy range. It has decreased from 0.06 (Mar 24) to 0.03, marking a decrease of 0.03.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.57. It has decreased from 0.63 (Mar 24) to 0.57, marking a decrease of 0.06.
- For Current Ratio (X), as of Mar 25, the value is 5.59. This value exceeds the healthy maximum of 3. It has increased from 4.14 (Mar 24) to 5.59, marking an increase of 1.45.
- For Quick Ratio (X), as of Mar 25, the value is 4.77. This value exceeds the healthy maximum of 2. It has increased from 3.42 (Mar 24) to 4.77, marking an increase of 1.35.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 6.04. This value is within the healthy range. It has increased from 0.72 (Mar 24) to 6.04, marking an increase of 5.32.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 5.70. This value is below the healthy minimum of 20. It has decreased from 12.25 (Mar 24) to 5.70, marking a decrease of 6.55.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 5.06. This value is below the healthy minimum of 20. It has decreased from 10.80 (Mar 24) to 5.06, marking a decrease of 5.74.
- For Earning Retention Ratio (%), as of Mar 25, the value is 94.30. This value exceeds the healthy maximum of 70. It has increased from 87.75 (Mar 24) to 94.30, marking an increase of 6.55.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 94.94. This value exceeds the healthy maximum of 70. It has increased from 89.20 (Mar 24) to 94.94, marking an increase of 5.74.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 106.72. This value is within the healthy range. It has increased from 97.89 (Mar 24) to 106.72, marking an increase of 8.83.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 79.80. This value is within the healthy range. It has increased from 73.31 (Mar 24) to 79.80, marking an increase of 6.49.
- For Enterprise Value (Cr.), as of Mar 25, the value is 12,381.23. It has decreased from 16,442.15 (Mar 24) to 12,381.23, marking a decrease of 4,060.92.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 2.80. This value is within the healthy range. It has decreased from 4.11 (Mar 24) to 2.80, marking a decrease of 1.31.
- For EV / EBITDA (X), as of Mar 25, the value is 4.85. This value is below the healthy minimum of 5. It has decreased from 8.75 (Mar 24) to 4.85, marking a decrease of 3.90.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 3.22. This value exceeds the healthy maximum of 3. It has decreased from 4.26 (Mar 24) to 3.22, marking a decrease of 1.04.
- For Retention Ratios (%), as of Mar 25, the value is 94.29. This value exceeds the healthy maximum of 70. It has increased from 87.74 (Mar 24) to 94.29, marking an increase of 6.55.
- For Price / BV (X), as of Mar 25, the value is 1.88. This value is within the healthy range. It has decreased from 2.91 (Mar 24) to 1.88, marking a decrease of 1.03.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 3.22. This value exceeds the healthy maximum of 3. It has decreased from 4.26 (Mar 24) to 3.22, marking a decrease of 1.04.
- For EarningsYield, as of Mar 25, the value is 0.13. This value is below the healthy minimum of 5. It has increased from 0.08 (Mar 24) to 0.13, marking an increase of 0.05.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Natco Pharma Ltd:
- Net Profit Margin: 42.51%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 30.11% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 24.78% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 79.8
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 4.77
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 10.7 (Industry average Stock P/E: 52.58)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.03
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 42.51%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | NATCO House, Road # 2, Banjara Hills, Hyderabad Telangana 500034 | investors@natcopharma.co.in http://www.natcopharma.co.in |
| Management | |
|---|---|
| Name | Position Held |
| Mr. V C Nannapaneni | Chairman & Managing Director |
| Mr. Rajeev Nannapaneni | Vice Chairman & CEO |
| Mr. P S R K Prasad | Director & Exe. VP (Corp. Engg. Services) |
| Dr. D Linga Rao | Director & President (Tech. Affairs) |
| Mr. D Vijaya Bhaskar | Independent Director |
| Mr. A D M Chavali | Independent Director |
| Dr. Kantipudi Suma | Independent Director |
| Mr. Nitin Jain | Independent Director |
| Mr. Lakshminarayana Bolisetty | Independent Director |
FAQ
What is the intrinsic value of Natco Pharma Ltd?
Natco Pharma Ltd's intrinsic value (as of 19 December 2025) is 1165.18 which is 27.06% higher the current market price of 917.00, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's 16,420 Cr. market cap, FY2025-2026 high/low of 1,489/660, reserves of ₹8,614 Cr, and liabilities of 10,430 Cr.
What is the Market Cap of Natco Pharma Ltd?
The Market Cap of Natco Pharma Ltd is 16,420 Cr..
What is the current Stock Price of Natco Pharma Ltd as on 19 December 2025?
The current stock price of Natco Pharma Ltd as on 19 December 2025 is 917.
What is the High / Low of Natco Pharma Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Natco Pharma Ltd stocks is 1,489/660.
What is the Stock P/E of Natco Pharma Ltd?
The Stock P/E of Natco Pharma Ltd is 10.7.
What is the Book Value of Natco Pharma Ltd?
The Book Value of Natco Pharma Ltd is 483.
What is the Dividend Yield of Natco Pharma Ltd?
The Dividend Yield of Natco Pharma Ltd is 0.65 %.
What is the ROCE of Natco Pharma Ltd?
The ROCE of Natco Pharma Ltd is 32.8 %.
What is the ROE of Natco Pharma Ltd?
The ROE of Natco Pharma Ltd is 28.0 %.
What is the Face Value of Natco Pharma Ltd?
The Face Value of Natco Pharma Ltd is 2.00.